[Dyslipidaemia and vascular risk. A new evidence based review]

Area of Science:

• Cardiology
• Endocrinology
• Preventive Medicine

Background:

• Dyslipidaemia is a primary risk factor for ischaemic heart disease, a leading global cause of mortality.
• Effective cardiovascular disease prevention relies on early detection and intervention for dyslipidaemia.
• Conflicting clinical guidelines for dyslipidaemia management create confusion among healthcare professionals.

Purpose of the Study:

• To provide an updated overview of dyslipidaemia management.
• To reconcile European and American guideline recommendations for various risk situations.
• To highlight atherogenic dyslipidaemia as a significant cardiovascular risk factor.

Main Methods:

• Comparative analysis of recent European and American clinical guidelines.
• Review of current therapeutic strategies for dyslipidaemia.
• Synthesis of evidence regarding atherogenic dyslipidaemia.

Main Results:

• Recent guidelines present diverse recommendations for achieving dyslipidaemia control objectives.
• Atherogenic dyslipidaemia is increasingly recognized as a distinct cardiovascular risk factor.
• Understanding guideline nuances is crucial for tailored patient management.

Conclusions:

• An updated understanding of dyslipidaemia guidelines is essential for effective clinical practice.
• Harmonizing guideline recommendations can improve patient outcomes.
• Targeting atherogenic dyslipidaemia is a key strategy in cardiovascular risk reduction.